Let’s Talk About Mold - with Ariana Thacker

The Mold Blind Spot: Ariana Thacker on Building the First Scalable Model of Care for CIRS Real Pharma, hosted by Na-Ri Oh and Ian Wendt Episode Summary Somewhere between one in four Americans carries a genetic profile that makes it hard to clear biotoxins from the body, and there is still no dedicated ICD-10 code for the illness that can follow. In this episode, Na-Ri and Ian talk with Ariana Thacker, founder and CEO of MoldCo, about how a mystery illness and a mold inspection turned a venture capitalist into the person building a scalable care model for a condition mainstream medicine still mostly misses. Ariana walks through her own diagnostic odyssey, the case for treating mold exposure as a public health issue rather than a niche one, and the treatment philosophy that has put MoldCo at odds with some other providers in the space. About Ariana Thacker Ariana Thacker is the founder and CEO of MoldCo, a digital health company building a scalable, evidence based virtual clinic for mold related illness and Chronic Inflammatory Response Syndrome (CIRS). She trained as a chemical engineer with a focus on biology and spent years in early stage and deep tech investing, building a portfolio of more than 70 companies through her venture firm, Conscience VC. In 2022, an unexplained health crisis, chronic fatigue, brain fog, night sweats, and a cluster of symptoms that resisted diagnosis across a dozen physicians, led her to discover toxic mold in her Miami apartment. She founded MoldCo in 2023. The company has raised $11 million to date, including an $8 million seed round co-led by Cantos and Collaborative Fund, and is now live in 48 states. What We Cover [00:00] Intro — Framing the episode: a condition Thacker says affects tens of millions of Americans, with almost no infrastructure in mainstream medicine built to catch it. [02:03] Ariana's origin story — An unexplained illness, months of inconclusive testing, and the mold inspection that finally connected the dots. [08:42] From patient to founder — Why Ariana spent time trying to recruit someone else to be CEO before deciding to take the job herself, and the biobank findings that convinced her the opportunity was bigger than her own case. [09:33] The scale of the problem — Water damage data, the genetic susceptibility angle, and Ariana's estimate of how many Americans are affected. [11:02] Why mold related illness slips through the cracks — No dedicated ICD-10 code, and a set of biomarkers most primary care and specialist panels never run. [12:09] The diagnostic odyssey — A dozen specialists, a friend's tip, and the Shoemaker-certified physician who finally confirmed a diagnosis. [16:20] Three policy fixes — An HHS-level mold commission, an environmental screening question at the annual physical, and a new ICD-10 code for the inflammatory response to mold. [18:37] Inside the Shoemaker Protocol — How MoldCo built its clinical model in collaboration with Dr. Ritchie Shoemaker, and what "90% of patients get 70 to 90% better" looks like in practice. [21:17] Why access is so limited — Roughly 30 Shoemaker-certified providers nationwide, wait lists, and a pricing landscape Ariana calls inconsistent to the point of price gouging. [23:08] The policy case — MoldCo's economic impact report, and early conversations with HHS, CMS, and ARPA-H. [27:02] How MoldCo actually works — The three questions behind the model (am I being exposed, is mold making me sick, how do I get better), and how a $150 to $300 a month price point pencils out. [31:50] Clinical quality control — Full-time staff physicians, weekly clinical huddles, and why Ariana says the price point doesn't mean corners get cut. [33:09] Treating patients still in the environment — What happens when remediation or relocation isn't realistic, and why re-exposure doesn't always mean starting over. [39:31] Where MoldCo draws the line — Why the team advises against antifungal treatment for CIRS, the research behind that position, and how it differs from the antifungal and naturopathic camps elsewhere in the field. [44:54] The HLA haplotype connection — Why some patients get hit much harder than others, and what having the genetic marker does and doesn't predict. [47:14] What's next — A forever chemicals program targeting PFAS, and the research behind it. [52:50] Closing — The middle school teacher who put Ariana on a path toward science, and where to find MoldCo. Notable Moments On not wanting the job she ended up taking: "I actually did not want to be CEO. I was interviewing multiple CEOs for this role. I just wanted to make sure that this was built and created, whether that was through me or, even more ideally at the time, someone else." On the hair loss that came with her diagnosis: "I actually had the most gratitude for the hair loss, because it anchored me in reality. There is something wrong here. There's an actual physical sign that something is wrong, versus a lot of the gaslighting and doubt I was getting through mainstream medicine." On why MoldCo won't budge on antifungals: "We're not a Shoemaker company, we're MoldCo. In light of new data and evidence, we're happy to change our opinion and our approach. But for now, what we're doing is working, and it's working great." On pricing: "There's no reason this can't be affordable and accessible for patients... there's no reason it should include a $13,000 price tag. I just think that's absurd." Mentioned in This Episode The Shoemaker Protocol, and the work of Dr. Ritchie Shoemaker and Dr. Scott McMahon MoldCo's economic impact report on the healthcare cost burden of mold related illness LabCorp, where MoldCo's lab panel is processed Conscience VC, Ariana's venture firm prior to founding MoldCo MoldCo's free environmental exposure guide and self-assessment